GlassScriptPhysician profile
Caleb Shea Deike
NPI 1457993065
$4,553.46
in general payments reported to CMS, 2019-2025
29 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $515 · 2023: $1,110 · 2024: $1,205 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.08 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $888.80 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $658.52 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $574.15 | 2021-2025 | |
| Mylan Specialty L.P. | $290.27 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $231.10 | 2022-2025 | |
| Novo Nordisk INC | $227.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $219.81 | 2021-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.99 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $177.54 | 2024-2025 | Veozah |
| Pfizer INC. | $132.82 | 2021-2025 | |
| Amgen INC. | $130.15 | 2022-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $123.47 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $96.88 | 2025 | |
| Cardiovascular Systems INC. | $84.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $80.03 | 2022-2024 | Abilify Maintena, Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $69.99 | 2025 | Omnipod |
| Corcept Therapeutics | $68.39 | 2024-2025 | Korlym |
| Neurocrine Biosciences, INC. | $63.51 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.66 | 2022-2024 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $32.73 | 2025 | Keveyis |
| Novartis Pharmaceuticals Corporation | $26.26 | 2024 | |
| Madrigal Pharmaceuticals | $24.98 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $23.14 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $21.38 | 2024 | Dexcom G6 Transmitter |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.11 | 2024 | Rexulti |
| Acella Pharmaceuticals, LLC | $16.41 | 2025 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2023 | Livalo |
| Merck Sharp & Dohme LLC | $12.44 | 2021 | |
| Orexo US, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Deike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.